Detalles de la búsqueda
1.
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
Int J Cancer
; 154(9): 1607-1615, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38196128
2.
The complexity of EGFR exon 19 deletion and L858R mutant cells as assessed by proteomics, transcriptomics, and metabolomics.
Exp Cell Res
; 424(1): 113503, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36731710
3.
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.
Int J Clin Oncol
; 29(6): 689-699, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38578596
4.
Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Int J Clin Oncol
; 2024 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38755516
5.
Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Int J Clin Oncol
; 29(6): 700-705, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38696053
6.
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(4): 355-362, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38353907
7.
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 545-550, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38517658
8.
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 551-558, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38526621
9.
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 559-563, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38538963
10.
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology.
Int J Clin Oncol
; 29(5): 535-544, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38494578
11.
Primary prophylaxis with G-CSF for patients with non-round cell soft tissue sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology.
Int J Clin Oncol
; 2024 Jun 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38865026
12.
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(6): 681-688, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38649648
13.
Effect of a Cyclooxygenase-2 Inhibitor in Combination with (-)-Epigallocatechin Gallate or Polyphenon E on Cisplatin-Induced Lung Tumorigenesis in A/J Mice.
Acta Med Okayama
; 77(1): 65-70, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36849147
14.
Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells.
Exp Cell Res
; 409(2): 112940, 2021 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34808132
15.
Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.
Cancer Immunol Immunother
; 70(1): 101-106, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32648165
16.
Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer.
Jpn J Clin Oncol
; 51(2): 279-286, 2021 Feb 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33049757
17.
Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404.
Jpn J Clin Oncol
; 51(8): 1269-1276, 2021 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34115855
18.
Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status.
Cancer Sci
; 111(10): 3739-3746, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32726470
19.
Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients.
Jpn J Clin Oncol
; 50(12): 1447-1453, 2020 Dec 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-32869100
20.
De Novo Carborane-Containing Macrocyclic Peptides Targeting Human Epidermal Growth Factor Receptor.
J Am Chem Soc
; 141(49): 19193-19197, 2019 12 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31752491